Piramal's GPR40 agonist set for US trial
This article was originally published in Scrip
Executive Summary
Piramal Enterprises, the diversified Indian pharmaceuticals-to-financial services group, has received US FDA investigational new drug approval for P11187, a selective agonist of the G-protein-coupled receptor GPR40, marking new progress for its in-house original R&D efforts.